摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-5-yl)ethyI)-5-methoxybenzoic acid

中文名称
——
中文别名
——
英文名称
3-(2-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-5-yl)ethyI)-5-methoxybenzoic acid
英文别名
3-(2-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-5-yl)ethyl)-5-methoxybenzoic acid;3-(2-(2-(4-(4-(2-Hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-5-yl)ethyl)-5-methoxybenzoic acid;3-[2-[2-[4-[4-(2-hydroxyethyl)piperazin-1-yl]anilino]pyrimidin-5-yl]ethyl]-5-methoxybenzoic acid
3-(2-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-5-yl)ethyI)-5-methoxybenzoic acid化学式
CAS
——
化学式
C26H31N5O4
mdl
——
分子量
477.563
InChiKey
PCCVUHCONKECLR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    35
  • 可旋转键数:
    10
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    111
  • 氢给体数:
    3
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE<br/>[FR] NOUVEAUX COMPOSÉS DE PYRIMIDINE ET DE PYRIDINE ET LEUR UTILISATION
    申请人:HUTCHISON MEDIPHARMA LTD
    公开号:WO2014139465A1
    公开(公告)日:2014-09-18
    The present invention relates to novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, wherein R1, R2, R3, R4, R5, X, Y and G are as defined in the description, to pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of FGFR, for example, cancer.
    本发明涉及通式(I)的新型嘧啶和吡啶化合物或其药学上可接受的盐,其中R1、R2、R3、R4、R5、X、Y和G如说明书中所定义,涉及含有它们的药物组合物、制备它们的方法以及它们在治疗对FGFR抑制有反应的疾病,例如癌症中的用途。
  • NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE
    申请人:HUTCHISON MEDIPHARMA LIMITED
    公开号:US20160024021A1
    公开(公告)日:2016-01-28
    The present invention relates to novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, Y and G are as defined in the description, to pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of FGFR, for example, cancer.
    本发明涉及公式(I)的新型嘧啶和吡啶化合物,或其药物可接受的盐,其中R1,R2,R3,R4,R5,X,Y和G如描述中所定义,以及包含它们的制药组合物,制备它们的过程以及它们在对抗需要抑制FGFR的疾病治疗中的用途,例如癌症。
  • NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF
    申请人:HUTCHISON MEDIPHARMA LIMITED
    公开号:US20160052926A1
    公开(公告)日:2016-02-25
    The present invention relates to novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, Y and G are as defined in the description, to pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of FGFR, for example, cancer.
    本发明涉及一种新的嘧啶和吡啶化合物,其化学式为(I)或其药物可接受的盐,其中R1、R2、R3、R4、R5、X、Y和G的定义如描述中所述,以及含有它们的制药组合物,制备它们的过程,以及它们在治疗对FGFR抑制有反应的疾病,例如癌症中的用途。
  • US9701680B2
    申请人:——
    公开号:US9701680B2
    公开(公告)日:2017-07-11
  • [EN] NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF<br/>[FR] NOUVEAUX COMPOSÉS PYRIMIDINES ET PYRIDINES ET LEUR UTILISATION
    申请人:HUTCHISON MEDIPHARMA LTD
    公开号:WO2014139145A1
    公开(公告)日:2014-09-18
    Provided are novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of FGFR, for example, cancer.
    提供了式(I)的新型嘧啶和吡啶化合物或其药用可接受的盐,含有它们的药物组合物,制备它们的方法,以及它们在对抗对FGFR抑制敏感的疾病(例如癌症)的治疗中的用途。
查看更多